Welcome to BioSeeker Group!

Cancer Vaccines Fantasy or Future?

Additional Information

Published Date Feb 1, 2005
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 175
PDF Fact Sheet View Fact Sheet for the report Cancer Vaccines Fantasy or Future? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Vaccines Fantasy or Future?.

    To find out more about Cancer Vaccines Fantasy or Future?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Vaccines Fantasy or Future? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way.

An example of difficulties and risks associated with this field is shown by Dendreon’s latest failure, in January 2005 of their late stage cancer vaccine candidate Provenge. The new and updated progress analysis report "Cancer Vaccines Fantasy or Future" by BioSeeker Group continues to provide the latest information and analysis on industry related as well as important academic activities.

Active immunotherapy strategies have emerged and progress in the molecular characterization of human tumors and a better understanding of tumor immunology has resulted in the discovery of tumor-associated antigens (TAAs). TAA-based vaccines are at present being evaluated. It is broadly admitted that therapeutic vaccines will initially and in the near future be efficient only on a limited tumor burden. Cancer vaccines ought to be used in an adjuvant setting, for instance in order to remove residual disease after surgical treatment of the tumor. As well, in light of the fact that some of these experimental vaccines can elicit immune and clinical responses even in patients with advanced cancer, cancer vaccines can also be considered for slowing down disease progression and conserve quality of life.

BioSeeker Group has since several years continuously studied the progress in cancer immunotherapy strategies. In this newly updated progress analysis we not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.

Reasons Why You Should Read This Report:

  • Get a solid background of what is happening in the Cancer Vaccine field.
  • Learn how the strategies have improved.
  • Make sure that you have the latest information about the most prominent Cancer Vaccine candidates.
  • Speed up your R&D by finding collaborators or partners.

Methodology

Introduction to cancer immunotherapy

Improved strategies

Progress analysis on cancer vaccine candidates:

Actimmune

Allovectin-7

Avicine

BEC2

Canvaxin

CeaVac

CaPVax. (DCVax).

Gastrimmune

GMK

LymphoCide

Melacine

M-Vax

MyVax

Oncophage

OncoVAX

Osidem

Ovarex

Provenge

Theratope

TroVax

Company Profiles

Appendix: Progress profiles on therapeutic candidates

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Vaccines Fantasy or Future?.
    To find out more about Cancer Vaccines Fantasy or Future?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Vaccines Fantasy or Future? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Targeted Therapeutics in Non-Small Cell Lung Cancer
With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC. Learn More


Large Pharma:2004 a year of Progress
BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Target Atlas in Thyroid Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More

Other selected research from the 'Vaccines' category:


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More


Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications. Learn More